Current and Future Challenges in the Development of Antimicrobial Agents
- 7 August 2012
- book chapter
- Published by Springer Nature
- No. 211,p. 45-65
Abstract
Micro-organisms exist to survive. Even in the absence of antimicrobial agents, many have determinants of resistance that may be expressed phenotypically, should the need arise. With the advent of the antibiotic age, as more and more drugs were developed to treat serious infections, micro-organisms (particularly bacteria) rapidly developed resistance determinants to prevent their own demise. The most important determinants of resistance have been in the Gram-positive and Gram-negative bacteria. Among Gram-positive bacteria, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) and penicillin-resistant Streptococcus pneumoniae (PRSP) have taxed researchers and pharmaceutical companies to develop new agents that are effective against these resistant strains. Among the Gram-negative bacteria, extended-spectrum beta-lactamase (ESBL) enzymes, carbapenemases (CREs) and the so-called amp-C enzymes that may be readily transferred between species of enterobacteriaceae and other facultative species have created multi-drug resistant organisms that are difficult to treat. Other resistance determinants have been seen in other clinically important bacterial species such as Neisseria gonorrhoeae, Clostridium difficile, Haemophilus influenzae and Mycobacterium tuberculosis. These issues have now spread to fungal agents of infection. A variety of modalities have been used to stem the tide of resistance. These include the development of niche compounds that target specific resistance determinants. Other approaches have been to find new targets for antimicrobial activity, use of combination agents that are effective against more than one target in the cell, or new delivery mechanism to maximize the concentration of antimicrobial agents at the site of infection without causing toxicity to the host. It is important that such new modalities have been proved effective for clinical therapy. Animal models and non-mammalian systems have been developed to determine if new agents will reach sufficient concentrations at infection sites to predict clinical efficacy without toxicity. It will also be key to consider antimicrobial stewardship as an important component of the continuing battle to prevent the development of antimicrobial resistance.Keywords
This publication has 55 references indexed in Scilit:
- High-Level Cefixime- and Ceftriaxone-Resistant Neisseria gonorrhoeae in France: NovelpenAMosaic Allele in a Successful International Clone Causes Treatment FailureAntimicrobial Agents and Chemotherapy, 2012
- Drosophila melanogaster as an Animal Model for the Study of Pseudomonas aeruginosa Biofilm Infections In VivoPLOS Pathogens, 2011
- Rational Design of α‐Helical Antimicrobial Peptides to Target Gram‐negative Pathogens, Acinetobacter baumannii and Pseudomonas aeruginosa: Utilization of Charge, ‘Specificity Determinants,’ Total Hydrophobicity, Hydrophobe Type and Location as Design Parameters to Improve the Therapeutic RatioChemical Biology & Drug Design, 2011
- Updated Functional Classification of β-LactamasesAntimicrobial Agents and Chemotherapy, 2010
- Characterization of a New Metallo-β-Lactamase Gene, bla NDM-1 , and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from IndiaAntimicrobial Agents and Chemotherapy, 2009
- Increase in Pneumococcus Macrolide Resistance, United StatesEmerging Infectious Diseases, 2009
- Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to AntibioticsAntimicrobial Agents and Chemotherapy, 2008
- Effects of net charge and the number of positively charged residues on the biological activity of amphipathic α‐helical cationic antimicrobial peptidesPeptide Science, 2008
- Reviews Of Anti‐infective Agents: New Agents for the Treatment of Fungal Infections: Clinical Efficacy and Gaps in CoverageClinical Infectious Diseases, 2006
- Activity of Retapamulin (SB-275833), a Novel Pleuromutilin, against Selected Resistant Gram-Positive CocciAntimicrobial Agents and Chemotherapy, 2006